Phosphonate Ester Synthesis via Seeded Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for reproducible manufacturing methods to obtain pharmaceutically active ingredients in chemically and morphologically pure, crystalline forms to ensure stability and consistency in pharmaceutical drug development, as different solid forms of active ingredients can exhibit varying properties affecting dissolution rates, bioavailability, and chemical stability.
Innovation Solution
A method for synthesizing high-purity, high-yield crystalline forms of phosphonic acid, [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl) ethoxy]methyl]mono[3-(hexadecyloxy)propyl] ester (Compound 1) through a series of recrystallizations, including seeding with morphic Form II and slow cooling, to produce morphic Form II, which is anhydrous and free of impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional manufacturing methods are used to obtain pharmaceutically active ingredients, then production can proceed with standard processes, but the chemical and morphological purity cannot be ensured, leading to inconsistent dissolution rates and bioavailability
Solution Approach 1:
The manufacturing process is divided into distinct sequential steps: initial crystallization to obtain crude product, followed by multiple recrystallization cycles (at least two) with controlled cooling rates, and final form control. Each step targets specific impurity removal and morphological refinement, transforming a single complex purification challenge into manageable sequential operations that achieve high chemical and morphological purity.
Solution Approach 2:
The process employs systematic parameter changes including controlled cooling rates (0.1-10°C/min), temperature ranges (20-80°C), and solvent selection to transition the material between different solid forms. By precisely adjusting these parameters during recrystallization, the method achieves reproducible morphological purity and chemical purity while maintaining process control.
2Adaptability or versatility
If different solid forms of active ingredient are used, then various properties such as dissolution rate and bioavailability can be optimized, but consistency and reproducibility of manufacturing become difficult to achieve
Solution Approach 1:
The method performs preliminary form control through seeded crystallization and controlled cooling before final product formation. By pre-establishing the desired crystal morphology through seeding with reference material and controlling the crystallization kinetics, the process ensures that the active ingredient adopts the intended solid form consistently, enabling both property optimization and manufacturing reproducibility.
Solution Approach 2:
The process incorporates feedback mechanisms through characterization techniques (XRPD, DSC, microscopy) to monitor and verify the solid form obtained. This feedback allows adjustment of crystallization parameters in subsequent batches to maintain consistent morphological purity and chemical purity, ensuring reliable reproduction of the desired solid form with optimized properties.
3Stability of the object's composition
If crystalline forms are used to improve chemical stability, then shelf-life and stability are enhanced, but the manufacturing process becomes more complex requiring controlled crystallization conditions
Solution Approach 1:
The method exploits phase transitions during controlled crystallization and recrystallization to transform the active ingredient into stable crystalline forms. By controlling temperature changes and solvent removal rates during these phase transitions, the process reliably produces chemically stable crystalline material with defined morphology, balancing the increased process complexity with significant stability benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves stable, high-purity crystalline forms of Compound 1 with improved chemical stability and reproducibility, suitable for large-scale pharmaceutical manufacturing, ensuring consistent properties and bioavailability.
Implementation Method 1
A method for synthesizing high-purity, high-yield crystalline forms of phosphonic acid through a series of recrystallizations, including seeding with morphic Form II and slow cooling
Implementation Method 2
slow cooling, to produce morphic Form II, which is anhydrous and free of impurities
Implementation Method 3
A method for synthesizing high-purity, high-yield crystalline forms of phosphonic acid through a series of recrystallizations
Implementation Method 4
morphic Form II, which is anhydrous and free of impurities
Data Source
AI summary
The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds.